1. The REDUCE-AMI trial showed no significant benefit of beta-blockers in reducing all-cause mortality or future myocardial infarction in patients with acute myocardial infarction and preserved left ventricular ejection fraction.

2. The trial included 5,020 patients who were randomized to either beta-blockade with metoprolol or bisoprolol or usual care, with follow-up over a median of 3.5 years.

3. Primary and secondary outcomes showed no significant differences between the beta-blocker and usual care groups.

4. Safety outcomes were similar between groups, and there was significant crossover and varying adherence to beta-blocker therapy over time.

5. The findings suggest a need to re-evaluate the routine use of beta-blockers in this patient population, emphasizing personalized treatment approaches and further research.